Filing Flows › ELI Lilly (LLY) › Other immunology revenue
ELI Lilly (LLY) Other immunology revenue by quarter
ELI Lilly's Other immunology revenue was $579M in Q3 2026 (third quarter 2026), +3% from Q2 2026. Over the last 4 quarters it ranged from $408M (Q2 2025) to $579M (Q3 2026).
| Quarter | Other immunology revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $579M | +3% | — |
| Q2 2026 | $561M | +19% | +38% |
| Q1 2026 | $470M | +15% | — |
| Q2 2025 | $408M | — | — |
Q3 2026 at a glance
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.
Questions
What is ELI Lilly's Other immunology revenue?
ELI Lilly's Other immunology revenue was $579M in Q3 2026 (third quarter 2026), +3% from Q2 2026.
How has ELI Lilly's Other immunology revenue changed?
Over the last 4 quarters it ranged from $408M (Q2 2025) to $579M (Q3 2026).